For: | Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol 2022; 28(39): 5691-5706 [PMID: 36338895 DOI: 10.3748/wjg.v28.i39.5691] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v28/i39/5691.htm |
Number | Citing Articles |
1 |
Kristine Griffett, Thomas P. Burris. Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1102469
|
2 |
Panagiotis Theofilis, Aikaterini Vordoni, Vasilis Tsimihodimos, Rigas G. Kalaitzidis. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers. High Blood Pressure & Cardiovascular Prevention 2023; 30(1): 63 doi: 10.1007/s40292-023-00558-5
|
3 |
Mahmoud Ibrahim, Ebtesam M. Ba‐Essa, Jason Baker, Avivit Cahn, Antonio Ceriello, Francesco Cosentino, Melanie J. Davies, Robert H. Eckel, Luc Van Gaal, Peter Gaede, Yehuda Handelsman, Samuel Klein, Richard David Leslie, Paolo Pozzilli, Stefano Del Prato, Francesco Prattichizzo, Oliver Schnell, Petar M. Seferovic, Eberhard Standl, Abraham Thomas, Jaakko Tuomilehto, Paul Valensi, Guillermo E. Umpierrez. Cardio‐renal‐metabolic disease in primary care setting. Diabetes/Metabolism Research and Reviews 2024; 40(3) doi: 10.1002/dmrr.3755
|
4 |
Amedeo Lonardo. Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review. Metabolism and Target Organ Damage 2024; 4(2) doi: 10.20517/mtod.2024.07
|
5 |
Damon J. DiSabato, Christina M. Marion, Katherine A. Mifflin, Anthony N. Alfredo, Kyleigh A. Rodgers, Kristina A. Kigerl, Phillip G. Popovich, Dana M. McTigue. System failure: Systemic inflammation following spinal cord injury. European Journal of Immunology 2024; 54(1) doi: 10.1002/eji.202250274
|
6 |
Maria Sole Valentino, Pierluigi Marzuillo, Claudia Esposito, Mario Bartiromo, Michele Nardolillo, Annalisa Valentina Villani, Alessandro Maresca, Giuseppe Furcolo, Stefano Guarino, Emanuele Miraglia del Giudice, Anna Di Sessa. The Impact of COVID-19 Pandemic Lockdown on the Relationship between Pediatric MAFLD and Renal Function. Journal of Clinical Medicine 2023; 12(5): 2037 doi: 10.3390/jcm12052037
|
7 |
Panagiotis Theofilis, Aikaterini Vordoni, Rigas G. Kalaitzidis. Trimethylamine N-Oxide Levels in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Metabolites 2022; 12(12): 1243 doi: 10.3390/metabo12121243
|
8 |
Michele Nardolillo, Fabiola Rescigno, Mario Bartiromo, Dario Piatto, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa. Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective. World Journal of Gastroenterology 2024; 30(15): 2081-2086 doi: 10.3748/wjg.v30.i15.2081
|
9 |
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes & Metabolism 2024; 50(1): 101506 doi: 10.1016/j.diabet.2023.101506
|
10 |
Carolina M. Perdomo, Nerea Martin-Calvo, Ana Ezponda, Francisco J. Mendoza, Gorka Bastarrika, Nuria Garcia-Fernandez, José I. Herrero, Inmaculada Colina, Javier Escalada, Gema Frühbeck. Epicardial and liver fat implications in albuminuria: a retrospective study. Cardiovascular Diabetology 2024; 23(1) doi: 10.1186/s12933-024-02399-5
|